Last reviewed · How we verify
NCT06340646
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
NA trial testing Return of Genetic Results: Biomarker information from cancer cells in Cholangiocarcinoma in 990 participants. Currently enrolling.
31 January 2027
Quick facts
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 990 |
| Start date | 18 October 2022 |
| Primary completion | 31 January 2027 |
| Estimated completion | 31 January 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Return of Genetic Results: Biomarker information from cancer cells
- Return of Genetic Results: Inherited mutations related to cancer
- Return of Genetic Results: Inherited mutations related to other medical issues
Conditions studied
- Cholangiocarcinoma — all drugs for Cholangiocarcinoma →
- Multiple Myeloma — all drugs for Multiple Myeloma →
- Colon Cancer — all drugs for Colon Cancer →
- Rectal Cancer — all drugs for Rectal Cancer →
Sponsor
Washington University School of Medicine
Who can join
18 and older, any sex, with Cholangiocarcinoma or Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimization Unit (EOU) will investigate the impact of this intervention on participant knowledge, expectations of benefit, personal utility, and decisional conflict.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06340646
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cholangiocarcinoma
Currently open trials in the same condition.
- NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
- NCT07291947 — PULSAR Combined With Immunotherapy and Chemotherapy · Phase 1, PHASE2 · recruiting
- NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
- NCT07263217 — Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury · NA · recruiting
- NCT07155525 — Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas · Phase 3 · recruiting
Other Washington University School of Medicine trials
Trials by the same sponsor.
- NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
- NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
- NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
- NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06340646 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
- Last refreshed: 11 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06340646.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing